Results 151 to 160 of about 21,749 (235)

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Surya Ayalasomayajula, Ednan K. Bajwa, Alexandra G. Cornell, Maria Jose Loureiro, Samuel S. Kim, Julia Richmond DiBello, Eric Sterner, Richard Chen, Islam R. Younis   +8 more
wiley   +1 more source

Does Secondary HFpEF Exist? Yes, but it Should not be Called HFpEF

Arquivos Brasileiros de Cardiologia
Humberto Villacorta, Pedro Schwartzmann
openaire   +2 more sources

GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review. [PDF]

Drugs Context
Roy E, Parent MC, Ducharme A.
europepmc   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Osteopontin in HFpEF

Journal of the American College of Cardiology, 2019
Fadi N. Salloum, Vinh Q. Chau
openaire   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart-liver metabolic axis perspective. [PDF]

Front Pharmacol
Wu X, Ma Y, Yin X, Liu J, Zhang Y.
europepmc   +1 more source

Prognostic Utility of the HFpEF-ABA Score for HFpEF Patients

JACC: Advances
Wengen Zhu, Linjuan Guo, Xi Chen, Min Ye
openaire   +1 more source

HDACs as a therapeutic target in HFpEF [PDF]

Nature Reviews Cardiology, 2020
openaire   +2 more sources

Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy. [PDF]

J Clin Med
Krasińska B, Krasiński Z, Urbanowicz T.   +2 more
europepmc   +1 more source